Oruka Therapeutics, Inc. ORKA
Set alert
95.43 USD -1.44 -1.49%
At close · Nov 2
95.43 0.00 0.00%
After hours · Nov 2, 4:33 PM ET
94.29 Day range 99.83
26.19 52-week range 113.08
- YTD
- +214.85%
- 1 year
- +238.76%
- Open
- 98.85
- Prev close
- 96.87
- Mkt cap
- 6.32B
- Vol
- 654.34K
- Avg vol
- 892.48K
- EPS
- -2.01
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 94.29
- High
- 99.83
- Forward P/E
- -33.34
- Beta
- -0.17
- Short ratio
- 5.86
- Inst. own
- 116.96%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 11, 2026
- 50-d avg
- 88.47
- 200-d avg
- 69.23
- 1y target
- 156.17
Analyst view
Consensus: strong buy
Strong buy
Price target (mean) 156.17 +63.6% upside
Now 95.43
- Target (low)
- 117.00
- Target (mean)
- 156.17
- Target (high)
- 200.00
Ratings (0m) 13 13 buy · 0 hold · 0 sell
- Strong buy2
- Buy11
- Hold0
- Sell0
- Strong sell0
Recommendation trend
- This month 13
- 1 month ago 13
- 2 months ago 13
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | -0.61832 | -0.79 – -0.41 | -0.55 | -12.4% | 0 | 0.0% | 9 |
| Next quarter | -0.6627 | -0.86 – -0.40 | -0.45 | -47.3% | 0 | 0.0% | 9 |
| Current year | -2.37 | -2.90 – -1.83 | -1.85 | -27.9% | 0 | 0.0% | 9 |
| Next year | -2.86 | -4.09 – -2.19 | -2.37 | -21.0% | 0 | 0.0% | 9 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 27, 2026 | Guggenheim | Reiterated | Buy | Buy |
| Oct 27, 2026 | Wedbush | Reiterated | Outperform | Outperform |
| Oct 19, 2026 | BTIG | Reiterated | Buy | Buy |
| Sep 24, 2026 | Wedbush | Reiterated | Outperform | Outperform |
| Sep 24, 2026 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Sep 3, 2026 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Aug 11, 2026 | Guggenheim | Reiterated | Buy | Buy |
| Aug 11, 2026 | Wedbush | Reiterated | Outperform | Outperform |
| Aug 11, 2026 | BTIG | Reiterated | Buy | Buy |
| Aug 3, 2026 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Jul 13, 2026 | BTIG | Reiterated | Buy | Buy |
| Jul 1, 2026 | UBS | Maintained | Buy | Buy |
| Jun 23, 2026 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| May 18, 2026 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| May 14, 2026 | BTIG | Reiterated | Buy | Buy |
| Apr 29, 2026 | HC Wainwright & Co. | Maintained | Buy | Buy |
| Apr 28, 2026 | UBS | Maintained | Buy | Buy |
| Apr 28, 2026 | Barclays | Maintained | Overweight | Overweight |
| Apr 27, 2026 | BTIG | Maintained | Buy | Buy |
| Apr 15, 2026 | Wedbush | Maintained | Outperform | Outperform |
| Apr 13, 2026 | Guggenheim | Reiterated | Buy | Buy |
| Apr 13, 2026 | BTIG | Maintained | Buy | Buy |
| Apr 13, 2026 | HC Wainwright & Co. | Maintained | Buy | Buy |
| Apr 9, 2026 | Guggenheim | Reiterated | Buy | Buy |
| Apr 7, 2026 | Barclays | Maintained | Overweight | Overweight |
| Apr 6, 2026 | UBS | Maintained | Buy | Buy |
| Apr 6, 2026 | Guggenheim | Maintained | Buy | Buy |
| Mar 16, 2026 | Leerink Partners | Maintained | Outperform | Outperform |
| Mar 13, 2026 | Barclays | Maintained | Overweight | Overweight |
| Mar 13, 2026 | BTIG | Reiterated | Buy | Buy |